The average one-year price target for Revolution Medicines (BIT:1RVMD) has been revised to €116.43 per share, reflecting an 11.57% increase from the previous estimate of €104.36 dated February 23, 2026. This average is based on analysts’ targets ranging from a low of €62.73 to a high of €151.87, and it represents a 39.44% increase from the last reported closing price of €83.50.
As of the latest data, 391 funds report positions in Revolution Medicines, marking a decrease of 291 funds or 42.67% in the last quarter. Total shares owned by institutions fell by 10.18% to 188,701K shares. Key shareholders include Farallon Capital Management (7.36% ownership), which decreased its holdings by 0.29%, and Janus Henderson Group (6.21% ownership), which increased its stake by 7.70%. Wellington Management Group reduced its holdings by 40.44%, while Paradigm Biocapital Advisors increased theirs by 6.34%.
